TerminatedPhase 2NCT01536067

Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia

Studying Waldenström Macroglobulinemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Roswell Park Cancer Institute
Principal Investigator
Seema Bhat, MD
Roswell Park Cancer Institute
Intervention
ofatumumab(biological)
Enrollment
3 enrolled
Eligibility
18 years · All sexes
Timeline
2012

Study locations (2)

Collaborators

National Cancer Institute (NCI) · GlaxoSmithKline

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01536067 on ClinicalTrials.gov

Other trials for Waldenström Macroglobulinemia

Additional recruiting or active studies for the same condition.

See all trials for Waldenström Macroglobulinemia →

← Back to all trials